Drugs / IGIV-HB Grifols
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00838071 | Oct 2003 → Jul 2004 | chronic hepatitis B virus infection | Grifols, S.A. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IGIV-HB Grifols | “Specific Anti-Hepatitis B Immunoglobulin (IGIV-HB Grifols)” NCT00838071 ↗ |
| Modality | Protein / enzyme biologic | “a new specific hepatitis B immune globulin” NCT00838071 ↗ |
| Route | Intravenous | “administered intravenously” NCT00838071 ↗ |